Leo drops phase III drug and closes factory in Australia

After a shrinking market potential and disappointing phase III results, Leo Pharma stops the development of one of its candidates and throttles down activities for the drug it was to replace.

Photo: Leo Pharma PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Related articles